Board Of Directors

Len Potter, JD


Leonard A. Potter is the President and Chief Investment Officer of Wildcat Capital Management, LLC, and the Chief Executive Officer of Infinity Q Capital Management, LLC. Both Wildcat and Infinity Q are registered investment advisors. From 2009 until forming Wildcat in 2011, Mr. Potter served as a consultant to Soros Fund Management LLC (“SFM”) and as the Chief Investment Officer of Salt Creek Hospitality, a private acquirer and owner of hospitality related assets that was sponsored by an affiliate of SFM. From 2002 through 2009, Mr. Potter was Managing Director – Soros Private Equity at SFM where, from May 2005 through July 2009, Mr. Potter served as co-head of the Private Equity group and a member of the Private Equity Investment Committee. From September 1998 until joining SFM, Mr. Potter was a Managing Director of Alpine Consolidated LLC, a private merchant bank, and from April 1996 through September 1998, Mr. Potter founded and served as a Managing Director of Capstone Partners LLC, a private merchant bank. Prior to founding Capstone Partners, Mr. Potter was an attorney specializing in mergers, acquisitions and corporate finance at Morgan, Lewis & Bockius and Willkie Farr & Gallagher. Mr. Potter has previously served, and continues to serve, as a board member of several public and private companies. Mr. Potter has a BA from Brandeis University and a JD degree from the Fordham University School of Law.

Mr. Ilan Hadar


Ilan brings over 20 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies. Ilan has been instrumental in building companies from start-ups to hundreds of millions of dollars in operations. He successfully took part in the development, approval, and launch of new pharmaceutical products in the U.S. and Israel. Ilan has also been responsible for leading the operations, R&D, manufacturing, regulatory, and corporate finance for premier healthcare companies in the U.S. and Israel.

Currently, Ilan is serving as the CEO of Painreform Ltd. (“PRFX”) in addition to Silenseed, Painreform proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post-surgically. Prior to joining Painreform and Silenseed, Ilan served as Country Manager Israel and CFO at Foamix Pharmaceuticals Ltd. (now NASDAQ: VYNE) since 2014, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., as well as a focus on capital markets and M&A. Prior to Foamix, Ilan was Finance Director at Pfizer Pharmaceutical Ltd., where he oversaw all commercial, financial and operational activities of the local entity. Prior to that, Ilan served as Finance Manager at HP Indigo Ltd, a world-leading company in digital printing. Prior to that, Ilan was Finance Director at BAE Systems (FTSE:BA), the third-largest defence company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2016, Ilan was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions, where he was successful in building the company from the incubator stage to a multinational, multi-million dollar revenue-generating company. Ilan serves on the Board of Directors at Kadimastem, a public Israeli biopharmaceutical company (TASE: KDST). Ilan received his MBA in Finance and Business Entrepreneurship and B.A. degree at The Hebrew University in Jerusalem, Israel.

Ilan Shiloah


Mr. Ilan Shiloah is a Co-Founder and the Chairman of the board in TheTime, an active incubator investing mainly in Israeli startup companies (amongst is TalkSpace). Mr. Shiloah also serves as the Chairman of the board and Managing partner in the venture capital First Time. Mr. Shiloah is the Chairman at McCann Erickson Ltd. (Israel) in the last 15 years,  beforehand he served 10 years as the company CEO, and served as a board member in McCann Erickson (Europe).

Dean Slagel


Dean Slagel, Managing Director of the corporate biotech venture investor Esperante, has 25 years of biotech and venture investing experience and a Masters of Business Administration. Following a global marketing management role at Tillotts Pharma, he spent 10 years with Ferring in global commercial operations and business development management. He has led Esperante since 2004, investing in a total of 23 companies across North America and Europe with 3 successful exits and 4 public listings. He is currently a Board Director of AMLo Biosciences and Oxford Cancer Biomarkers and a Board Observer at Arquer Diagnostics.

Joseph Lavi